Improving testicular cancer pharmacotherapy through the use of pharmacogenomic approaches

0.3/100,000 inhabitants. It represents 1% of male neoplasms and 5% of urological tumors, with 3-10 new cases occurring per 100,000 males/per year. The most common subtypes of TCa are seminom and non-seminoma germ cell. Seminoma TCa represents about 30% t

Detalles Bibliográficos
Autor: Quiñones-Sepúlveda, Luis Abel
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2014
País:Chile
Idioma:inglés
OAI Identifier:oai:repositorio.anid.cl:10533/228658
Acceso en línea:https://hdl.handle.net/10533/228658
Access Level:acceso abierto
id CL_a09d5338d2e2efa4b7adca5433c2e721
oai_identifier_str oai:repositorio.anid.cl:10533/228658
network_acronym_str CL
network_name_str Chile
repository_id_str
spelling Quiñones-Sepúlveda, Luis Abel2017https://hdl.handle.net/10533/228658http://purl.org/coar/access_right/c_abf2Improving testicular cancer pharmacotherapy through the use of pharmacogenomic approachesQuiñones-Sepúlveda, Luis Abel2018-11-29T15:37:07Z2022-07-07T21:28:17Z20142018-11-29T15:37:07Z2022-07-07T21:28:17Z20170.3/100,000 inhabitants. It represents 1% of male neoplasms and 5% of urological tumors, with 3-10 new cases occurring per 100,000 males/per year. The most common subtypes of TCa are seminom and non-seminoma germ cell. Seminoma TCa represents about 30% tRegularFONDECYTFONDECYT11404341140434virtual::16798-1https://hdl.handle.net/10533/228658enghandle/10533/111556handle/10533/111541handle/10533/108045http://www.remedypublications.com/annals-of-urological-research/articles/pdfs_folder/aur-v1-id1004.pdfAtribución-NoComercial-SinDerivadas 3.0 Chilehttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/info:eu-repo/semantics/openAccessImproving testicular cancer pharmacotherapy through the use of pharmacogenomic approachesAnnals of Urological ResearchArticuloinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttps://hdl.handle.net/10533/228658FONDECYThttp://purl.org/coar/resource_type/c_2df8fbb1221ec375-6cfd-4de7-83f8-dba26b2747e0virtual::16798-1221ec375-6cfd-4de7-83f8-dba26b2747e0virtual::16798-110533/228658oai:repositorio.anid.cl:10533/2286582023-07-24 19:30:04.589https://repositorio.anid.clRepositorio ANIDaletelier@anid.cl
dc.title.none.fl_str_mv Improving testicular cancer pharmacotherapy through the use of pharmacogenomic approaches
dc.title.journal.none.fl_str_mv Annals of Urological Research
title Improving testicular cancer pharmacotherapy through the use of pharmacogenomic approaches
spellingShingle Improving testicular cancer pharmacotherapy through the use of pharmacogenomic approaches
Quiñones-Sepúlveda, Luis Abel
title_short Improving testicular cancer pharmacotherapy through the use of pharmacogenomic approaches
title_full Improving testicular cancer pharmacotherapy through the use of pharmacogenomic approaches
title_fullStr Improving testicular cancer pharmacotherapy through the use of pharmacogenomic approaches
title_full_unstemmed Improving testicular cancer pharmacotherapy through the use of pharmacogenomic approaches
title_sort Improving testicular cancer pharmacotherapy through the use of pharmacogenomic approaches
dc.creator.none.fl_str_mv Quiñones-Sepúlveda, Luis Abel
author Quiñones-Sepúlveda, Luis Abel
author_facet Quiñones-Sepúlveda, Luis Abel
author_role author
description 0.3/100,000 inhabitants. It represents 1% of male neoplasms and 5% of urological tumors, with 3-10 new cases occurring per 100,000 males/per year. The most common subtypes of TCa are seminom and non-seminoma germ cell. Seminoma TCa represents about 30% t
publishDate 2014
dc.date.annoconcurso.none.fl_str_mv 2014
dc.date.issued.none.fl_str_mv 2017
dc.date.accessioned.none.fl_str_mv 2018-11-29T15:37:07Z
2022-07-07T21:28:17Z
dc.date.available.none.fl_str_mv 2018-11-29T15:37:07Z
2022-07-07T21:28:17Z
dc.type.none.fl_str_mv Articulo
dc.type.driver.none.fl_str_mv info:eu-repo/semantics/article
dc.type.openaire.none.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.folio.none.fl_str_mv 1140434
1140434
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/10533/228658
identifier_str_mv 1140434
url https://hdl.handle.net/10533/228658
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.contest.none.fl_str_mv handle/10533/111556
dc.relation.instrument.none.fl_str_mv handle/10533/111541
dc.relation.program.none.fl_str_mv handle/10533/108045
dc.relation.uri.none.fl_str_mv http://www.remedypublications.com/annals-of-urological-research/articles/pdfs_folder/aur-v1-id1004.pdf
dc.rights.none.fl_str_mv Atribución-NoComercial-SinDerivadas 3.0 Chile
http://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rights.driver.none.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv Atribución-NoComercial-SinDerivadas 3.0 Chile
http://creativecommons.org/licenses/by-nc-nd/3.0/cl/
eu_rights_str_mv openAccess
repository.name.fl_str_mv Repositorio ANID
repository.mail.fl_str_mv aletelier@anid.cl
_version_ 1843518586147045376
score 15,812455

Similares en LA Referencia